VIENNA, Va., June 19 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM) will conduct a live interview on http://www.MN1.com at 11:00
a.m. eastern time this Tuesday, June 20, 2006. Interested parties may go to
http://www.MN1.com to listen to management's review of operations and
discussion of future prospects. This live broadcast is available to anyone
at any computer connected to the Internet.
MN1.com is the only online destination that brings real microcap news
to investors and features live interaction with companies from the AMEX,
Bulletin Board, and Pink Sheets. Featuring Live Press Conferences, All-Day
Live Trading Commentary, Analyst Profiles, Interactive Forums, News Items,
and "The MicroBlog," MN1.com gives microcap investors the information
source necessary to trade in the markets. MN1.com boasts being the largest
true news company reporting on microcap traded stocks.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company's lead product Multikine is
cleared to enter global Phase III clinical trials in advanced primary head
and neck cancer patients. CEL-SCI's other products, which are currently in
pre- clinical stage and are funded with U.S. government support, have shown
protection against a number of diseases in animal tests and are being
tested against diseases associated with bio-defense and avian flu.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
http://www.MN1.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
